CRL earnings call for the period ending March 31, 2020.
James Foster became the CEO of Charles River Laboratories International, Inc. (NYSE:CRL) in 1992. This analysis aims...
Charles River Laboratories Schedules First-Quarter 2020 Earnings Release and Conference Call.
Horizon Kinetics LLC, a New York-based investment advisory firm founded in 1994, released its Q1 2020 Commentary – a copy of which is available for download here. It has over 70 employees and is led by Murray Stahl. Its investment strategy is long-term and contrarian oriented, and the fund usually holds a concentrated portfolio with original […]
Q1 2020 Charles River Laboratories International Inc Earnings Call
British company’s shares up 35% this year as demand for health care information analysis grows Continue reading...
Charles River today announced that it has entered into a partnership with Deciphex, a leader in preclinical digital pathology software-as-a-service.
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
To the annoyance of some shareholders, Charles River Laboratories International (NYSE:CRL) shares are down a...
It's been a good week for Charles River Laboratories International, Inc. (NYSE:CRL) shareholders, because the company...
Q4 2019 Charles River Laboratories International Inc Earnings Call
Those holding Charles River Laboratories International (NYSE:CRL) shares must be pleased that the share price has...
Charles River Laboratories Announces First-Quarter 2020 Results
Charles River Laboratories to present at Barclays Global Healthcare Conference
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Charles River (CRL) delivered earnings and revenue surprises of 24.32% and 2.07%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories appoints Nancy C. Andrews, M.D., Ph.D., Dean Emerita of Duke University’s School of Medicine, to its Board of Directors
Medpace is building a base and near a possible buy range ahead of its earnings report expected around Apr. 28.
Charles River Laboratories International (NYSE:CRL) shares have had a really impressive month, gaining 30%, after some...
Charles River Laboratories International, Inc. (NYSE:CRL), which is in the life sciences business, and is based in...